OncRef

Clinical Trial: NCT03965468

Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:ETOP IBCSG Partners Foundation
Information Provided By:ETOP IBCSG Partners Foundation
Last Update Posted:2026-10-05

Study Overview

Brief Summary

A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in patients with histologically-confirmed synchronous oligo-metastatic non-small cell lung cancer (NSCLC).

Official Title

A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer

Conditions

Non-small Cell Lung Cancer, Stage IV, Oligometastasis

Intervention / Treatment

  • Drug: Durvalumab
  • Drug: Carboplatin
  • Drug: Paclitaxel
  • Radiation: Stereotactic body radiation therapy (SBRT)
  • Procedure: Surgical resection - definitive local treatment.
  • Radiation: Radical radiotherapy - definitive local treatment.
  • Drug: Tremelimumab

Other Study ID Numbers

  • ETOP 14-18
  • 2018-003011-22
  • ESR-17-13224
  • 2018

Start Date (Actual)

2019-11-19

Primary Completion Date (Estimated)

2026-12

Study Completion Date (Estimated)

2026-12

Enrollment (Estimated)

96

Study Type

Interventional

Phase

Phase 2